OHR Pharmaceutical (NASDAQ:OHRP) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07), Bloomberg Earnings reports.

OHR Pharmaceutical (NASDAQ OHRP) opened at $0.31 on Thursday. OHR Pharmaceutical has a twelve month low of $0.27 and a twelve month high of $2.18.

A number of brokerages have recently issued reports on OHRP. ValuEngine upgraded shares of OHR Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Roth Capital cut shares of OHR Pharmaceutical from a “buy” rating to a “neutral” rating and set a $7.00 price objective for the company. in a report on Friday, January 5th. Finally, Zacks Investment Research cut shares of OHR Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, October 26th.

A hedge fund recently raised its stake in OHR Pharmaceutical stock. Vanguard Group Inc. increased its position in shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) by 0.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 812,418 shares of the biotechnology company’s stock after purchasing an additional 5,481 shares during the quarter. Vanguard Group Inc. owned approximately 1.45% of OHR Pharmaceutical worth $520,000 as of its most recent SEC filing. 8.32% of the stock is owned by hedge funds and other institutional investors.

WARNING: “OHR Pharmaceutical (OHRP) Posts Earnings Results, Meets Estimates” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2018/02/15/ohr-pharmaceutical-ohrp-posts-earnings-results-meets-estimates.html.

About OHR Pharmaceutical

OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

Earnings History for OHR Pharmaceutical (NASDAQ:OHRP)

Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.